drugset / Trial / NCT00771134

Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

NCT00771134

Phase 2 Terminated 105 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy and safety of Lu AA39959 in the treatment of depression in patients with bipolar disorder.

Timeline

Start
2008-12
Primary completion
2009-06
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AA39959 Unknown 15 mg
Comparator Quetiapine Small molecule 300 mg

Indications